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June 9, 2009:2197–200have added to the area under the receiver-operator character-
istic curve for the standard risk factors’ ability to prognosticate.
We think that there has not been and will not be a major
breakthrough in prevention, akin to what has dramatically
occurred in diagnostic testing and intervention, until risk
factors are used not for risk assessment, but to identify treatable
causal factors after risk has more accurately been established by
the level of subclinical atherosclerosis (5).
. To those who raise cost effectiveness concerns related to
widespread screening for subclinical atherosclerosis, reduction
in the cost of calcium scanning to the level of mammography
will make it the most cost-effective modality.
. Finally, in both secondary and primary prevention, there has
been a misplaced focus on simple changes in the treated risk
factors, for example, low-density lipoprotein, rather than on
measures of subclinical atherosclerosis and disease activity and
endothelial function to evaluate the response of the disease,
rather than the risk factors, to treatment.
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2004;93:73–5.correspondencLetter to the editor
o Benefit From Cardiac
esynchronization Therapy in
symptomatic Patients
e congratulate Linde et al. (1) on the meticulously carried out
EVERSE (REsynchronization reVErses Remodeling in Systolic
eft vEntricular dysfunction) trial that addressed the question of
he clinical benefit of cardiac resynchronization therapy (CRT) in
atients with New York Heart Association (NYHA) functional
lass II and I heart failure (1). Unfortunately, the composite
rimary end point as defined per the study protocol was negative.
till, the authors conclude that CRT, in combination with optimal
edical treatment ( defibrillator), reduces the risk for heart
ailure hospitalizations and improves ventricular structure and
unction in NYHA functional class II and I. In our opinion, the pater statement is not supported by the presented data, which
hows no benefit for NYHA functional class I patients (odds ratio:
.87; 95% confidence interval: 0.37 to 2.03) in their subgroup
nalysis (Fig. 4 of Linde et al. [1]).
This disagreement raises the more philosophical question:
hether these subgroup analyses make sense if the primary end
oint is negative—maybe due to a lack of statistical power? It
eems that the well-known players such as wide QRS and low left
entricular ejection fraction are positive predictors for CRT success
ut not NYHA functional class I. Another intriguing finding of
his subgroup analysis is that patients on diuretics did improve,
hereas those not on diuretics did not. However, the use of
iuretics reduced mortality and prevented hospital admissions in
his patient population, which raises the question of whether the
se of diuretics by themselves may have accounted for the
ocumented beneficial effect (clinical composite end point, hospi-
alizations) in the CRT ON group and whether this confounding
ariable was corrected for in the main analysis (2).
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eply
e thank Dr. Osswald and colleagues for their interest in our
aper (1). The REVERSE (REsynchronization reVErses Remod-
ling in Systolic left vEntricular dysfunction) study was designed as
ne population of New York Heart Association (NYHA) func-
ional class I to II heart failure (HF) patients. We agree that the
rimary end point did not reach statistical significance (2), with
6% of patients worsened in the cardiac resynchronization therapy
CRT) ON group and 21% in the CRT OFF group (p  0.10).
he clinical composite response was designed for severe HF
atients and, to our knowledge, has not previously been used in
ildly symptomatic or asymptomatic HF patients (3).
The fact that the primary end point did not reach statistical
ignificance despite substantial improvement in left ventricular
LV) dimensions accompanied by a significantly reduced time to
rst HF related hospitalization might be due to the difference in
tility of this end point or that the observation period was not long
nough to demonstrate effects in NYHA functional class I to II
atients. Dr. Osswald and colleagues are concerned about the
